These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

184 related articles for article (PubMed ID: 25058176)

  • 1. Renaissance of antibiotics against difficult infections: Focus on oritavancin and new ketolides and quinolones.
    Van Bambeke F
    Ann Med; 2014 Nov; 46(7):512-29. PubMed ID: 25058176
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Oritavancin - a new semisynthetic lipoglycopeptide agent to tackle the challenge of resistant gram positive pathogens.
    Das B; Sarkar C; Schachter J
    Pak J Pharm Sci; 2013 Sep; 26(5):1045-55. PubMed ID: 24035967
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The role of solithromycin in the management of bacterial community-acquired pneumonia.
    Van Bambeke F; Tulkens PM
    Expert Rev Anti Infect Ther; 2016; 14(3):311-24. PubMed ID: 26848612
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Oritavancin: A Novel Lipoglycopeptide.
    Mattox J; Belliveau P; Durand C
    Consult Pharm; 2016 Feb; 31(2):86-95. PubMed ID: 26842686
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Chemical structure and pharmacokinetics of novel quinolone agents represented by avarofloxacin, delafloxacin, finafloxacin, zabofloxacin and nemonoxacin.
    Kocsis B; Domokos J; Szabo D
    Ann Clin Microbiol Antimicrob; 2016 May; 15(1):34. PubMed ID: 27215369
    [TBL] [Abstract][Full Text] [Related]  

  • 6. In vitro activity of nemonoxacin (TG-873870), a novel non-fluorinated quinolone, against clinical isolates of Staphylococcus aureus, enterococci and Streptococcus pneumoniae with various resistance phenotypes in Taiwan.
    Chen YH; Liu CY; Lu JJ; King CH; Hsueh PR
    J Antimicrob Chemother; 2009 Dec; 64(6):1226-9. PubMed ID: 19833635
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Solithromycin: A novel ketolide antibiotic.
    Buege MJ; Brown JE; Aitken SL
    Am J Health Syst Pharm; 2017 Jun; 74(12):875-887. PubMed ID: 28432048
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [New antibacterial agents on the market and in the pipeline].
    Kern WV
    Internist (Berl); 2015 Nov; 56(11):1255-63. PubMed ID: 26475603
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A comparative review of the lipoglycopeptides: oritavancin, dalbavancin, and telavancin.
    Guskey MT; Tsuji BT
    Pharmacotherapy; 2010 Jan; 30(1):80-94. PubMed ID: 20030476
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Delafloxacin for the treatment of respiratory and skin infections.
    Bassetti M; Della Siega P; Pecori D; Scarparo C; Righi E
    Expert Opin Investig Drugs; 2015 Mar; 24(3):433-42. PubMed ID: 25604710
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Oritavancin: a potential weapon in the battle against serious Gram-positive pathogens.
    Crandon J; Nicolau DP
    Future Microbiol; 2008 Jun; 3(3):251-63. PubMed ID: 18505390
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Nemonoxacin (TG-873870) for treatment of community-acquired pneumonia.
    Lai CC; Lee KY; Lin SW; Chen YH; Kuo HY; Hung CC; Hsueh PR
    Expert Rev Anti Infect Ther; 2014 Apr; 12(4):401-17. PubMed ID: 24579813
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Looking for the new preparations for antibacterial therapy III. New antimicrobial agents from the quinolones group in clinical trials.
    Karpiuk I; Tyski S
    Przegl Epidemiol; 2013; 67(3):455-60, 557-61. PubMed ID: 24340560
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Oritavancin: an investigational lipoglycopeptide antibiotic.
    Karaoui LR; El-Lababidi R; Chahine EB
    Am J Health Syst Pharm; 2013 Jan; 70(1):23-33. PubMed ID: 23261897
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Delafloxacin, a non-zwitterionic fluoroquinolone in Phase III of clinical development: evaluation of its pharmacology, pharmacokinetics, pharmacodynamics and clinical efficacy.
    Van Bambeke F
    Future Microbiol; 2015; 10(7):1111-23. PubMed ID: 26119479
    [TBL] [Abstract][Full Text] [Related]  

  • 16. New agents in development for the treatment of bacterial infections.
    Abbanat D; Morrow B; Bush K
    Curr Opin Pharmacol; 2008 Oct; 8(5):582-92. PubMed ID: 18761107
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Differentiating the Pharmacodynamics and Toxicology of Macrolide and Ketolide Antibiotics.
    Fernandes P; Pereira D; Watkins PB; Bertrand D
    J Med Chem; 2020 Jun; 63(12):6462-6473. PubMed ID: 31644280
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Oritavancin: a novel lipoglycopeptide active against Gram-positive pathogens including multiresistant strains.
    Bouza E; Burillo A
    Int J Antimicrob Agents; 2010 Nov; 36(5):401-7. PubMed ID: 20729040
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Ketolides: pharmacological profile and rational positioning in the treatment of respiratory tract infections.
    Van Bambeke F; Harms JM; Van Laethem Y; Tulkens PM
    Expert Opin Pharmacother; 2008 Feb; 9(2):267-83. PubMed ID: 18201149
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Oritavancin for skin infections.
    Anderson DL
    Drugs Today (Barc); 2008 Aug; 44(8):563-75. PubMed ID: 18846268
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.